Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
t-cell tags : Biotech save search
Fortress Biotech Subsidiary Helocyte Announces Option Agreement with City of Hope for Exclusive Worldwide Rights to use a Novel Bispecific CMV/HIV CAR T Cell Therapy (optionally in combination with Triplex) for the Treatment of Adults Living with HIV-1
Published: 2023-10-16 (Crawled : 13:00) - globenewswire.com
AZNCF | News | $140.3 -4.19% 1.5K
|
Health Technology
|
| O: -4.43%
H: 3.6%
C: 3.6%
FBIO | $1.785 -1.38% -1.4% 120K
|
Health Technology
|
| O: 0.34%
H: 4.12%
C: -4.81%
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: -1.07%
H: 2.0%
C: 1.82%
biotech worldwide hope cell treatment city agreement therapy living
CERo Therapeutics, Inc. and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Advancing the Development of Next Generation Engineered T Cell Therapeutics
Published: 2023-06-05 (Crawled : 13:00) - feed.businesswire.com
PBAX 4 | $5.85 -11.11% 6.5K
|
n/a
| Email alert
Add to watchlist
biotech cell acquisition therapeutics agreement
PDS Biotech Announces Preclinical Publication in Peer Reviewed Viruses Journal Showing Superior CD4 T Cell Induction by Infectimune™
Published: 2023-02-16 (Crawled : 15:20) - globenewswire.com
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: -1.48%
H: 0.55%
C: 0.08%
PDSB | $3.26 1.88% 1.84% 450K
|
Health Technology
|
| O: -0.11%
H: 2.74%
C: -1.37%
preclinical biotech publication
Portage Biotech Acquires Outstanding Minority Interest of Invariant Natural Killer T cell (iNKT) Agonist Platform
Published: 2022-07-20 (Crawled : 13:20) - globenewswire.com
PRTG | $0.265 9.23% 8.45% 180K
|
Mining, Quarrying, and Oil and ...
|
| O: -1.23%
H: 19.49%
C: 7.45%
biotech platform
Oncolytics Biotech® Announces Publication of Preclinical Data Demonstrating the Synergistic Anti-Cancer Activity of Pelareorep Combined with CAR T Cell Therapy in Solid Tumors in Science Translational Medicine
Published: 2022-04-14 (Crawled : 12:00) - biospace.com/
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: -3.21%
H: 1.99%
C: -0.66%
biotech preclinical therapy pre-clinical
Sana Biotechnology to Present Preclinical Data on its Engineered Hypoimmune Allogeneic CAR T Cells at the 2022 American Association for Cancer Research Annual Meeting
Published: 2022-03-08 (Crawled : 22:00) - globenewswire.com
SANA | $8.58 6.06% 5.71% 1.2M
|
|
| O: 3.73%
H: 6.92%
C: 5.94%
america technology research cel preclinical cancer biotech iot t-cell pre-clinical
Adaptive Biotechnologies Announces New Data Demonstrating ImmunoSEQ® Technology Can Identify T-Cell Receptors Associated with Crohn’s Disease
Published: 2022-02-18 (Crawled : 17:00) - globenewswire.com
ADPT | $2.595 0.58% 0.39% 2M
|
Commercial Services
|
| O: -0.77%
H: 1.76%
C: -4.73%
immunoseq technology disease cel biotech iot t-cell
Gracell Biotechnologies Doses First Patients in First-in-Human Clinical Trial Evaluating GC012F, its Dual-Targeting FasTCAR-T Therapy, in B-Cell Non-Hodgkin's Lymphoma
Published: 2022-02-17 (Crawled : 14:00) - biospace.com/
GRCL | $10.25 -0.29% 6.4M
|
Manufacturing
|
| O: 0.53%
H: 2.65%
C: -5.82%
gc012 car-t trial cel therapy biotech iot t-cell
SQZ Biotechnologies Announces Publication of Comprehensive Preclinical Research on SQZ® APC’s Ability to Overcome Fundamental Biological Barrier to Effective and Efficient Killer T Cell Activation
Published: 2022-02-01 (Crawled : 12:30) - biospace.com/
SQZ | $0.435 0.0% 30M
|
Health Technology
|
| O: 19.91%
H: 0.0%
C: -1.85%
sqz research cel preclinical biotech iot t-cell pre-clinical
TCR² Therapeutics and Arbor Biotechnologies Establish Collaboration to Advance Allogeneic TRuC-T Cell Therapies
Published: 2022-01-04 (Crawled : 20:00) - biospace.com/
TCRR 4 | $1.48 3.38% 3.9M
|
Health Technology
|
| O: -0.42%
H: 0.0%
C: 0.0%
therapeutics cel collaboration biotech iot therapy t-cell
Sana Biotechnology Presentations at 2021 ASH Annual Meeting Highlight Progress with Platforms and CAR T Cell Programs
Published: 2021-12-12 (Crawled : 16:20) - globenewswire.com
SANA | $8.58 6.06% 5.71% 1.2M
|
| Email alert
Add to watchlist
technology presentation biotech iot platform t-cell
SQZ Biotechnologies Lead Cell Therapy Candidate Generated Monotherapy Clinical Response Correlated with Substantial CD8 T Cell Tumor Infiltration in HPV+ Solid Tumor at Highest Dose
Published: 2021-12-02 (Crawled : 12:30) - biospace.com/
SQZ | $0.435 0.0% 30M
|
Health Technology
|
| O: -10.45%
H: 5.31%
C: -5.72%
hpv therapy biotech iot t-cell
Gracell Biotechnologies Granted FDA Orphan Drug Designation for FasTCAR-enabled BCMA/CD19 Dual-targeting CAR-T Cell Therapy Candidate GC012F for the Treatment of Multiple Myeloma
Published: 2021-11-19 (Crawled : 12:00) - biospace.com/
GRCL | $10.25 -0.29% 6.4M
|
Manufacturing
|
| O: 21.78%
H: 4.25%
C: -19.25%
gc012 treatment fda orphan drug therapy car-t biotech drug iot granted t-cell designation
Gracell Biotechnologies to Present Preclinical Results of TruUCAR-enabled CD19/CD7 Dual-Directed Allogeneic CAR-T Cell Therapy (GC502) for B-Cell Malignancies at the 63rd ASH Annual Meeting
Published: 2021-11-04 (Crawled : 13:00) - prnewswire.com
GRCL | $10.25 -0.29% 6.4M
|
Manufacturing
| Email alert
Add to watchlist
therapy car-t results biotech iot preclinical t-cell pre-clinical
Adaptive Biotechnologies Launches T-Detect™ COVID, First Clinical T-Cell Based Test for Patients to Confirm Recent or Prior COVID-19 Infection
Published: 2021-02-23 (Crawled : 13:01) - globenewswire.com
ADPT | $2.595 0.58% 0.39% 2M
|
Commercial Services
|
| O: -1.27%
H: 2.57%
C: 1.36%
covid test biotech iot t-cell injection infections
PDS Biotech and Farmacore Announce Blanver to Join Consortium to Commercialize Novel Versamune®-Based T-Cell Inducing COVID-19 Vaccine
Published: 2021-02-22 (Crawled : 14:01) - globenewswire.com
PDSB | $3.26 1.88% 1.84% 450K
|
Health Technology
|
| O: 1.19%
H: 21.33%
C: 6.85%
covid biotech vaccine iot t-cell commercialization
PDS Biotech Releases White Paper Detailing the Potential of the Versamune® Platform in Overcoming a Major Limitation of Immuno-OncologyPromotes in-vivo tumor-attacking killer T-cells to facilitate cancer treatment
Published: 2021-01-14 (Crawled : 15:00) - biospace.com/
PDSB | $3.26 1.88% 1.84% 450K
|
Health Technology
|
| O: 1.15%
H: 8.37%
C: 4.94%
cancer biotech t-cell potential
Legend Biotech Announces FDA Clearance of the IND for LB1901, an Investigational Autologous Anti-CD4 CAR-T Therapy for Relapsed or Refractory T-Cell Lymphoma
Published: 2020-12-14 (Crawled : 16:00) - biospace.com/
LEGN | News | $45.205 -4.73% -4.97% 1.1M
|
Health Technology
|
| O: 2.1%
H: 9.14%
C: 4.64%
fda fda clearance biotech therapy car-t t-cell clearance
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.